[go: up one dir, main page]

TW200509930A - Methods and compositions for treating rheumatoid arthritis - Google Patents

Methods and compositions for treating rheumatoid arthritis

Info

Publication number
TW200509930A
TW200509930A TW093118691A TW93118691A TW200509930A TW 200509930 A TW200509930 A TW 200509930A TW 093118691 A TW093118691 A TW 093118691A TW 93118691 A TW93118691 A TW 93118691A TW 200509930 A TW200509930 A TW 200509930A
Authority
TW
Taiwan
Prior art keywords
methods
compositions
rheumatoid arthritis
integrin
treating rheumatoid
Prior art date
Application number
TW093118691A
Other languages
English (en)
Inventor
Theodore A Yednock
Stephen B Freedman
Ivan Lieberburg
Michael A Pleiss
Andrei Konradi
George Shopp
Elizabeth Messersmith
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200509930(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of TW200509930A publication Critical patent/TW200509930A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
TW093118691A 2003-06-25 2004-06-25 Methods and compositions for treating rheumatoid arthritis TW200509930A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48221103P 2003-06-25 2003-06-25

Publications (1)

Publication Number Publication Date
TW200509930A true TW200509930A (en) 2005-03-16

Family

ID=33551975

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093118691A TW200509930A (en) 2003-06-25 2004-06-25 Methods and compositions for treating rheumatoid arthritis

Country Status (12)

Country Link
US (2) US20050074451A1 (zh)
EP (2) EP1635822A4 (zh)
JP (2) JP2007526230A (zh)
AR (1) AR044927A1 (zh)
AU (2) AU2004251750A1 (zh)
CA (2) CA2528723A1 (zh)
CL (1) CL2004001621A1 (zh)
NZ (1) NZ544367A (zh)
PE (1) PE20050232A1 (zh)
TW (1) TW200509930A (zh)
UY (1) UY28391A1 (zh)
WO (2) WO2005000244A2 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1706399A1 (en) * 2004-01-23 2006-10-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EP1737461B1 (en) 2004-03-15 2012-12-12 PTC Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
WO2005111020A2 (en) * 2004-04-30 2005-11-24 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
AR050425A1 (es) * 2004-07-08 2006-10-25 Elan Pharm Inc Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas
CA2588607A1 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation
ES2309817T3 (es) 2004-12-02 2008-12-16 Can-Fite Biopharma Ltd. Tratamiento de inflamacion.
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US8030328B2 (en) 2005-05-20 2011-10-04 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives
NZ564836A (en) * 2005-07-08 2011-10-28 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
CA2624450C (en) * 2005-09-29 2014-02-04 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2009055427A2 (en) * 2007-10-22 2009-04-30 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
JP2011528321A (ja) * 2008-06-21 2011-11-17 ケンバー，エルエルシー ニュートリゲノミクス方法および組成
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
CN105616410A (zh) * 2009-07-30 2016-06-01 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
ES2731052T3 (es) 2009-08-10 2019-11-13 Active Biotech Ab Tratamiento de la enfermedad de Huntington usando laquinimod
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
KR20150135552A (ko) * 2010-03-03 2015-12-02 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
WO2011109531A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
ES2614807T3 (es) 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
JP2015511940A (ja) 2012-02-03 2015-04-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
CA2862346A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3015069A1 (en) 2014-10-30 2016-05-04 Universitätsklinikum Jena Apparatus for suspended ultrasonography and corresponding method
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
JP6820282B2 (ja) * 2016-02-05 2021-01-27 Ｅａファーマ株式会社 スルホンアミド誘導体及びそれを含有する医薬組成物
ES2797298T3 (es) 2016-02-10 2020-12-01 Becton Dickinson France Procedimiento para evaluar la estabilidad de una formulación a base de proteína
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
JP7401864B2 (ja) * 2018-03-05 2023-12-20 国立大学法人横浜国立大学 ナノ微粒子、及びナノ微粒子の製造方法、並びに抗腫瘍剤
WO2020046964A1 (en) 2018-08-27 2020-03-05 Sydlik Stefanie A Chelator-functionalized glycosaminoglycans
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1080503A (en) * 1965-07-02 1967-08-23 Smith & Nephew Substituted acetic acids and a process for their preparation
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
AU8823498A (en) * 1997-07-31 1999-02-22 American Home Products Corporation Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
IL133640A0 (en) * 1997-07-31 2001-04-30 Elan Pharm Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US20020198172A1 (en) * 1997-12-01 2002-12-26 Sandage Bobby W. Method of treating motor neuron diseases and demyelinating diseases with citicoline
WO2000043372A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
BR0007663A (pt) * 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
WO2001056994A1 (en) * 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
PE20020384A1 (es) * 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Also Published As

Publication number Publication date
AU2004251754A2 (en) 2005-01-06
CL2004001621A1 (es) 2005-03-28
CA2528723A1 (en) 2005-01-06
AR044927A1 (es) 2005-10-12
WO2005000244A3 (en) 2005-09-29
AU2004251754A1 (en) 2005-01-06
PE20050232A1 (es) 2005-04-01
AU2004251750A2 (en) 2005-01-06
CA2529873A1 (en) 2005-01-06
EP1635822A4 (en) 2009-06-24
EP1635871A2 (en) 2006-03-22
US20050065192A1 (en) 2005-03-24
WO2005000246A2 (en) 2005-01-06
NZ544367A (en) 2009-12-24
WO2005000244A2 (en) 2005-01-06
US20050074451A1 (en) 2005-04-07
EP1635871A4 (en) 2007-07-18
EP1635822A2 (en) 2006-03-22
JP2007524626A (ja) 2007-08-30
JP2007526230A (ja) 2007-09-13
UY28391A1 (es) 2004-12-31
AU2004251750A1 (en) 2005-01-06
US7605166B2 (en) 2009-10-20
WO2005000246A3 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
TW200509930A (en) Methods and compositions for treating rheumatoid arthritis
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
AU2003285874A8 (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
EA200600275A1 (ru) Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
EP1575509A4 (en) EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHOD OF USE THEREOF
CL2010000788A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
IL168058A (en) Antibody preferentially linked to cell Ca125 / 0722p relative to ca125 / 0722p deciduous cell, the pharmaceutical composition containing it and its use in the preparation of a drug
EA200600254A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
BRPI0407058A (pt) Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
CY1112750T1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
JO3000B1 (ar) مركبات أجسام مضادة .
DE60236646D1 (de) Anti-VEGF-2 Antikörper
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
AU9399501A (en) Therapeutic antibodies
MXPA03010747A (es) Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
NZ607886A (en) Nogo receptor binding protein
MXPA03003902A (es) Polipeptidos de proquineticina, composiciones relacionadas y metodos.
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
PT1200126E (pt) Utilização de anticorpos monoclonais específicos de cd28 para a preparação de uma composição farmacêutica para o tratamento de infecções virais
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело